Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Results from an active pharmacovigilance study in central Italy

• Main Authors: Giancarlo Ripabelli (Author), Michela Lucia Sammarco (Author), Antonio D'Amico (Author), Roberta De Dona (Author), Mariagrazia Iafigliola (Author), Albino Parente (Author), Nicandro Samprati (Author), Arturo Santagata (Author), Carmen Adesso (Author), Anna Natale (Author), Michela Anna Di Palma (Author), Fabio Cannizzaro (Author), Roberto Romano (Author), Antonietta Licianci (Author), Manuela Tamburro (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

This survey investigated on adverse events after vaccination with mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine in children aged 5-11 years in central Italy through active surveillance reporting. During December 2021-January 2022, parents of children who undergone vaccination were interviewed u...